As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator“s biologic products. But scientific challenges remain due to the complexity of both the manuf
Dieses Ebook kaufen – und ein weitere GRATIS erhalten!
Format PDF ● Seiten 444 ● ISBN 9781466579705 ● Verlag CRC Press ● Erscheinungsjahr 2013 ● herunterladbar 6 mal ● Währung EUR ● ID 2715426 ● Kopierschutz Adobe DRM
erfordert DRM-fähige Lesetechnologie